Literature DB >> 19269141

Emerging fluoroquinolone-non-susceptible group A streptococci in two different paediatric populations.

Pierre Robert Smeesters1, Anne Vergison, Dioclécio Campos Junior, Laurence Van Melderen.   

Abstract

Clonal emergence of group A streptococci (GAS) with reduced susceptibility to fluoroquinolones (FQs) has been increasingly reported. Non-susceptibility is associated with various point mutations in the target-encoding genes and has only been described in a few emm types. We used a well-characterised GAS clinical paediatric collection from Brussels (Belgium) and Brasília (Brazil) to analyse the molecular basis of FQ non-susceptibility. GAS strains were tested for ciprofloxacin susceptibility and were screened for mutations in DNA gyrase- and topoisomerase IV-encoding genes. Genetic relationships between the different emm types were assessed by phylogenetic analysis of the whole surface-exposed part of the M protein. A high proportion (22.5%) of ciprofloxacin-non-susceptible isolates (minimal inhibitory concentration > or = 2mg/L) was found among the Belgian strains. They belonged mostly to emm type 6 (87%). In Brazil, 6% of the isolates, belonging to seven distantly related emm types, were non-susceptible. Our phylogenetic analysis showed that non-susceptibility may arise in various genetic backgrounds. Sequence comparison of the quinolone resistance-determining regions (QRDRs) of the ParC- and ParE-encoding genes from susceptible and non-susceptible isolates revealed that most of the mutations were found in both classes of isolates, indicating an emm type-linked polymorphism. In conclusion, we observed a clonal spreading of non-susceptible emm type 6 GAS strains in Brussels and a polyclonal distribution of non-susceptible isolates in Brazil. All the Brazilian and Belgian emm type 6 strains displayed a S79A/F mutation in parC that convincingly explains the non-susceptible phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269141     DOI: 10.1016/j.ijantimicag.2009.01.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  7 in total

1.  Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.

Authors:  Renato Pires; Carmen Ardanuy; Dora Rolo; Ana Morais; António Brito-Avô; José Gonçalo-Marques; Josefina Liñares; Ilda Santos-Sanches
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 2.  Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance.

Authors:  Rob J L Willems; William P Hanage; Debra E Bessen; Edward J Feil
Journal:  FEMS Microbiol Rev       Date:  2011-07-04       Impact factor: 16.408

Review 3.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

4.  Antimicrobial susceptibility patterns, emm type distribution and genetic diversity of Streptococcus pyogenes recovered in Brazil.

Authors:  Glauber P Arêas; Rôde B B Schuab; Felipe P G Neves; Rosana R Barros
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-10-28       Impact factor: 2.743

5.  Identification and Characterization of Fluoroquinolone Non-susceptible Streptococcus pyogenes Clones Harboring Tetracycline and Macrolide Resistance in Shanghai, China.

Authors:  Yinfang Shen; Jiehao Cai; Mark R Davies; Chi Zhang; Kun Gao; Dan Qiao; Haoqin Jiang; Weilei Yao; Yuefang Li; Mei Zeng; Mingliang Chen
Journal:  Front Microbiol       Date:  2018-03-23       Impact factor: 5.640

6.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

7.  Effect of subinhibitory concentrations of fluoroquinolones on biofilm production by clinical isolates of Streptococcus pyogenes.

Authors:  Kannan Balaji; Ramalingam Thenmozhi; Shunmugiah Karutha Pandian
Journal:  Indian J Med Res       Date:  2013-05       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.